Renal Cancer: New Drug shows promise

Dr. Robert Motzen at Memorial Sloan Kettering is testing a new drug, SU11248 which is showing promising activity in renal cancer patients.

Reference: Dr. Motzen, G.U. Oncology Dept.; at MSKCC

Webmaster

November 19, 2004